Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NASDAQ:PRAX NASDAQ:TGTX NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.86-0.1%$44.72$25.83▼$84.00$8.85B0.237.75 million shs5.37 million shsPRAXPraxis Precision Medicines$314.41+2.0%$311.35$37.19▼$366.52$8.59B2.74532,673 shs282,210 shsTGTXTG Therapeutics$54.87-0.1%$47.75$25.28▼$59.30$8.41B1.62.32 million shs3.41 million shsVCELVericel$46.64-2.4%$39.57$28.95▼$48.75$2.44B1.07588,527 shs472,154 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals-0.06%+0.34%+134.57%+104.54%+162.88%PRAXPraxis Precision Medicines+2.01%-3.26%+16.44%-8.20%+486.26%TGTXTG Therapeutics-0.11%-3.94%+6.54%+55.31%+41.27%VCELVericel-2.45%-0.77%+19.19%+30.72%+25.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.86-0.1%$44.72$25.83▼$84.00$8.85B0.237.75 million shs5.37 million shsPRAXPraxis Precision Medicines$314.41+2.0%$311.35$37.19▼$366.52$8.59B2.74532,673 shs282,210 shsTGTXTG Therapeutics$54.87-0.1%$47.75$25.28▼$59.30$8.41B1.62.32 million shs3.41 million shsVCELVericel$46.64-2.4%$39.57$28.95▼$48.75$2.44B1.07588,527 shs472,154 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals-0.06%+0.34%+134.57%+104.54%+162.88%PRAXPraxis Precision Medicines+2.01%-3.26%+16.44%-8.20%+486.26%TGTXTG Therapeutics-0.11%-3.94%+6.54%+55.31%+41.27%VCELVericel-2.45%-0.77%+19.19%+30.72%+25.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.29Hold$78.27-6.66% DownsidePRAXPraxis Precision Medicines 2.95Moderate Buy$563.5079.22% UpsideTGTXTG Therapeutics 2.56Moderate Buy$53.33-2.80% DownsideVCELVericel 2.43Hold$55.5019.00% UpsideCurrent Analyst Ratings BreakdownLatest VCEL, PRAX, CRNX, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026VCELVericel Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $54.007/13/2026PRAXPraxis Precision Medicines Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/13/2026PRAXPraxis Precision Medicines The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$447.007/13/2026PRAXPraxis Precision Medicines The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$447.007/13/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$70.00 ➝ $77.007/8/2026CRNXCrinetics Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$85.00(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$7.70M1,148.34N/AN/A$9.71 per share8.64PRAXPraxis Precision Medicines$8.55M1,025.23N/AN/A$34.85 per share9.02TGTXTG Therapeutics$616.29M13.63$2.80 per share19.60$4.08 per share13.45VCELVericel$276.26M8.62$0.54 per share86.07$7.01 per share6.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/4/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8619.1918.661.3865.95%88.73%43.44%8/3/2026 (Estimated)VCELVericel$16.52M$0.42111.0555.52N/A7.35%6.41%4.61%7/30/2026 (Estimated)Latest VCEL, PRAX, CRNX, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026CRNXCrinetics Pharmaceuticals-$1.23N/AN/AN/A$14.84 millionN/A8/3/2026Q2 2026PRAXPraxis Precision Medicines-$3.6684N/AN/AN/A$1.25 millionN/A8/3/2026Q2 2026TGTXTG Therapeutics$0.3170N/AN/AN/A$228.98 millionN/A7/30/2026Q2 2026VCELVericel-$0.04N/AN/AN/A$72.70 millionN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/7/2026Q1 2026VCELVericel-$0.15-$0.12+$0.03-$0.12$63.68 million$68.43 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A18.6018.56PRAXPraxis Precision MedicinesN/A15.8815.88TGTXTG Therapeutics1.285.815.12VCELVericelN/A5.184.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%PRAXPraxis Precision Medicines67.84%TGTXTG Therapeutics58.58%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals3.80%PRAXPraxis Precision Medicines3.00%TGTXTG Therapeutics8.87%VCELVericel7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.04 millionOptionableTGTXTG Therapeutics290153.08 million139.51 millionOptionableVCELVericel30051.07 million47.19 millionOptionableVCEL, PRAX, CRNX, and TGTX HeadlinesRecent News About These CompaniesVericel (NASDAQ:VCEL) Raised to "Buy" at Wall Street Zen2 hours ago | americanbankingnews.comVericel (NASDAQ:VCEL) Upgraded by Wall Street Zen to Buy Rating2 hours ago | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Consensus Rating of "Hold" by BrokeragesJuly 17 at 4:07 AM | americanbankingnews.comVericel (NASDAQ:VCEL) Sets New 52-Week High - Still a Buy?July 16 at 12:19 PM | marketbeat.comVericel to Report Second Quarter 2026 Financial Results on July 30, 2026July 16 at 8:30 AM | globenewswire.comFifth Third Bancorp Purchases 255,465 Shares of Vericel Corporation $VCELJuly 16 at 3:43 AM | marketbeat.comVericel (NASDAQ:VCEL) Stock Price Down 5.9% - Here's What HappenedJuly 14, 2026 | marketbeat.comVericel Stock Short Interest Report | NASDAQ:VCEL | BenzingaJuly 13, 2026 | benzinga.comVericel Corporation (NASDAQ:VCEL) Receives Average Rating of "Hold" from AnalystsJuly 12, 2026 | marketbeat.comGranite Investment Partners LLC Buys 48,056 Shares of Vericel Corporation $VCELJuly 10, 2026 | marketbeat.comIs Vericel (NASDAQ:VCEL) Emerging As A Small-Cap Healthcare Story?July 9, 2026 | kalkinemedia.comKVericel (NASDAQ:VCEL) Reaches New 1-Year High - Still a Buy?July 9, 2026 | marketbeat.comWhich Is a Better Investment, Syndax Pharmaceuticals, Inc. or Vericel Corporation Stock?July 8, 2026 | aaii.comALouisiana State Employees Retirement System Makes New $721,000 Investment in Vericel Corporation $VCELJuly 7, 2026 | marketbeat.comConestoga Capital Advisors LLC Raises Stock Holdings in Vericel Corporation $VCELJuly 2, 2026 | marketbeat.comVericel (NASDAQ:VCEL) Insider Sells 2,732 Shares of StockJuly 1, 2026 | insidertrades.comVericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really SuggestsJune 27, 2026 | fool.comVericel (NASDAQ:VCEL) Insider Sean Flynn Sells 15,000 Shares of StockJune 23, 2026 | insidertrades.comVericel CorporationJune 9, 2026 | edition.cnn.comVericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026June 9, 2026 | globenewswire.comVericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million MoreMay 30, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026SK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026VCEL, PRAX, CRNX, and TGTX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$83.86 -0.05 (-0.06%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$83.92 +0.06 (+0.07%) As of 07/17/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Praxis Precision Medicines NASDAQ:PRAX$314.41 +6.21 (+2.01%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$314.74 +0.32 (+0.10%) As of 07/17/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.TG Therapeutics NASDAQ:TGTX$54.87 -0.06 (-0.11%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$55.43 +0.56 (+1.03%) As of 07/17/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Vericel NASDAQ:VCEL$46.64 -1.17 (-2.45%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$46.64 -0.01 (-0.01%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
